Diabetes

Mini-dose glucagon may halt post-exercise hypoglycemia

(HealthDay)—Mini-dose glucagon (MDG) is an effective approach for preventing exercise-induced hypoglycemia in patients with type 1 diabetes, according to a study published online May 18 in Diabetes Care.

Diabetes

Plasma volume changes may mediate effects of empagliflozin

(HealthDay)—The reduction in risk of cardiovascular (CV) death with empagliflozin is most mediated by changes in hematocrit and hemoglobin, according to research published online Dec. 4 in Diabetes Care.

Diabetes

Brain glucose responses diminish with diabetes, obesity

(HealthDay)—The rise of brain glucose levels is blunted during hyperglycemia in adults with obesity and type 2 diabetes mellitus (T2DM), according to a study published online Oct. 19 in JCI Insight.

Diabetes

Tofogliflozin most effective with high baseline insulin

(HealthDay)—The sodium glucose co-transporter 2 inhibitor tofogliflozin is effective for reducing fasting plasma glucose and body weight, particularly in patients with a high insulin level at baseline, according to a study ...

Diabetes

Fasting plasma glucose, HbA1c linked to alzheimer's in T2DM

(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), fasting plasma glucose (FPG) visit-to-visit variation, represented by the coefficient of variation (CV), and hemoglobin A1c (HbA1c) CV are independently associated ...

page 2 from 8